Free tool
FAERS Monitor: Enbrel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103795 or its brand name (Enbrel, Etanercept). Reports on generic versions are filed under their own applications.
Reports
597,166
Serious
216,189
36% of reports
Hospitalization
66,992
Death reported
17,505
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective75,667
- injection site pain56,857
- rheumatoid arthritis47,136
- arthralgia45,566
- pain43,715
- injection site erythema41,077
- fatigue30,777
- joint swelling25,864
- pain in extremity25,734
- psoriasis25,160
- headache25,036
- injection site swelling23,301
- off label use22,780
- injection site pruritus22,130
- injection site reaction20,969
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,194 |
| 2005 | 1,836 |
| 2006 | 8,806 |
| 2007 | 17,520 |
| 2008 | 16,649 |
| 2009 | 14,437 |
| 2010 | 22,274 |
| 2011 | 29,182 |
| 2012 | 42,296 |
| 2013 | 46,953 |
| 2014 | 41,070 |
| 2015 | 57,540 |
| 2016 | 58,757 |
| 2017 | 59,690 |
| 2018 | 49,137 |
| 2019 | 30,610 |
| 2020 | 26,238 |
| 2021 | 17,083 |
| 2022 | 17,132 |
| 2023 | 13,528 |
| 2024 | 11,931 |
| 2025 | 7,857 |
| 2026 | 5,446 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,456,993 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 47,136 | 24.3 | 24.0 | 619,026 |
| injection site erythemaSignal | 41,077 | 16.9 | 16.7 | 414,581 |
| injection site pruritusSignal | 22,130 | 16.9 | 16.6 | 222,129 |
| injection site reactionSignal | 20,969 | 15.0 | 14.8 | 191,094 |
| injection site swellingSignal | 23,301 | 14.9 | 14.7 | 211,903 |
| joint swellingSignal | 25,864 | 9.3 | 9.2 | 152,040 |
| psoriasisSignal | 25,160 | 8.2 | 8.1 | 128,513 |
| injection site painSignal | 56,857 | 7.8 | 7.7 | 278,010 |
| arthralgiaSignal | 45,566 | 4.2 | 4.2 | 101,373 |
| pain in extremitySignal | 25,734 | 3.3 | 3.2 | 37,637 |
| painSignal | 43,715 | 2.6 | 2.6 | 41,963 |
| drug ineffectiveSignal | 75,667 | 2.1 | 2.1 | 42,927 |
| headache | 25,036 | 1.4 | 1.4 | 3,119 |
| fatigue | 30,777 | 1.4 | 1.4 | 3,636 |
| off label use | 22,780 | 0.9 | 0.9 | 187 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.